The default drug development program includes three milestones, or Type B meetings. The earliest is the Pre-IND Meeting, the second is the End of Phase 2 (EOP2) Meeting, and the third milestone is the Pre-NDA Meeting.
View this resource Bookmark this resource
FDA Milestones meetings – Type B
Published by IRDiRC
Regulatory AffairsEarly Access SupportScientific AdviceRegulatory AdviceMilestone MeetingPre-NDA MeetingEnd of Phase 2 Meeting